Health-related quality of life (HRQOL) is diminished in patients infected with both hepatitis C virus (HCV) and human immunodeficiency virus (HIV), but the effect of HIV/HCV coinfection on HRQOL is unknown. We compared the HRQOL of urban HIV/HCV coinfected patients with that of patients infected with either HCV or HIV alone. We then compared the 3 groups with a US population sample, adjusting for demographic characteristics. HRQOL for the group of HIV/HCV coinfected patients was statistically similar to that of HRQOL in patients with either HCV or HIV alone, but the 3 groups had a significantly decreased HRQOL than did the adjusted US population. Using multivariate techniques, we determined that age, unemployment, injection drug use, and depression were associated with impaired HRQOL. These findings underscore the importance of a multidisciplinary approach to the treatment of these patient populations.
Both hepatitis C virus (HCV) and HIV type 1 have emerged as significant public health problems in the United States and Europe [1, 2] . In the United States, at least 4,000,000 individuals are infected with HCV, and 1900,000 individuals are infected with HIV [1, 2] . Approximately 10% of the HCV-infected population in the United States is coinfected with HIV. Thirty percent of HIV-infected patients are coinfected with HCV, with a prevalence of coinfection of 50%-70% among HIVinfected inner-city injection drug users [1] [2] [3] [4] [5] [6] .
Health-related quality of life (HRQOL) is increasingly recognized as an important measure for assessing the burden of chronic diseases. Studies suggest that HCV infection significantly reduces HRQOL, even in the absence of cirrhosis, and that successful treatment of HCV is associated with an improvement in HRQOL [7] [8] [9] [10] [11] . Results of initial studies involving HIV-infected patients suggest that HIV-infection is also associated with reduced HRQOL, with evidence that concurrent psychiatric conditions and illicit drug use significantly impair HRQOL for these patients [12] [13] [14] . However, results of studies on the effects of CD4 lymphocyte count, HIV load, and HAART on HRQOL have been contradictory [12, 13, 15, 16] .
The impact of HCV/HIV coinfection on HRQOL is unknown. Most available data have been limited to HCV infection, with information obtained largely from patients entering multicenter IFN treatment trials, a highly selected patient group [7, [9] [10] [11] . The objectives of this study were therefore to evaluate HRQOL in a large urban cohort of HIV/HCV coinfected patients and to compare the HRQOL of coinfected patients with that of urban patients infected with either HIV or HCV alone. The impact of coinfection and the variables contributing to HRQOL were then analyzed by multivariate techniques.
PATIENTS, MATERIALS, AND METHODS
Study population. This was a cross-sectional study comprising patients enrolled in our prospective natural history cohort study of chronic HCV and HIV infection (Hepatitis and AIDS Liver Outcomes [HALO] study) between August 2000 and April 2002. Patients were recruited from hepatology and infectious diseases clinics at Boston Medical Center and at the Veterans Affairs Boston Healthcare System, Jamaica Plain Campus. The following 3 groups of patients were enrolled: 136 HIV/ HCV coinfected patients, 110 patients with only HCV infection, and 53 patients with only HIV infection. Criteria for inclusion in this study included detectable HCV antibody and RNA levels (for the purpose of verifying chronic infection in HCV-infected patients). Excluded from the study were an additional 64 coinfected patients and 34 patients infected with HCV alone, because of an unavailable or undetectable HCV load at the time of study enrollment. Twenty-one patients refused to participate in the study. The study protocol was reviewed and approved by the institutional review board at each participating institution, and all participants provided written informed consent.
Survey materials. Patients completed a detailed, studyspecific questionnaire used in the HALO study and underwent a physical examination, and their medical records were reviewed. Only laboratory values obtained within 6 months before enrollment were recorded, although measurements of HCV antibody level and HCV load performed at any time were accepted. The questionnaire included specific questions on drug and alcohol use, employment, education, and income. HRQOL was assessed using the Hepatitis Quality of Life questionnaire (QualityMetric), a survey that has been validated for patients with chronic HCV infection and includes the generic SF-36 survey, 3 additional generic scales, and 2 hepatitis-specific scales [17] . In this article, we have confined the analysis to the SF-36 components, because the HCV-specific questions were not applicable to the group infected with HIV alone, and because a proportion of patients in the coinfected group were unable to answer these questions (i.e., they were unaware of their HCV infection status).
Permission to use the Hepatitis Quality of Life questionnaire was obtained from the publisher. Because of concerns about the literacy rate in this inner-city population, the survey was administered by 2 trained interviewers, rather than self administered. Normative population data for SF-36 questionnaire scores were obtained from the National Survey of Functional Health Status [18, 19] . These data were based on a sample of 2474 noninstitutionalized adults from the general US population and were gathered from October 1990 through December 1990.
Statistical analysis. Descriptive statistics were calculated using x 2 analysis for categorical data and analysis of variance (ANOVA) or Student's t test for continuous data. SF-36 scores were calculated for each subscale by summing the scores of their component items and converting the sum to a scale ranging from 0 to 100, with 100 corresponding to the best possible quality of life. Summaries of mental component scores (MCS) and physical component scores (PCS) were calculated using SAS software, version 8.1 (SAS) [18] . The analysis in this article is limited to the SF-36 components, in particular, the 8 component subscales and the 2 summary scales (i.e., the MCS and PCS). The subscales comprise perceptions of physical functioning, role limitations (physical and mental), bodily pain, general health, vitality, social function, and mental health [8] . MCS and PCS summarize the perceptions of mental and physical health.
Mean SF-36 subscale scores and summary-scale scores for the study groups were compared using ANOVA. The power of this study to detect a 10-point difference in PCS and MCS between the groups was 99%. Mean SF-36 scores for the study groups were compared with those of control subjects from the general US population using ANOVA, adjusting for the age, race, and sex distribution of the study sample. Predictors of HRQOL in the HCV-infected patients and in the HIV-infected patients were evaluated by linear regression analysis, using a separate model for the PCS and MCS. Data on patients infected with HIV alone and those coinfected with HIV/HCV were included in the HIV infection model, and data on patients infected with HCV alone and those coinfected with HIV/HCV were included in the HCV infection model. Variables with a P value of !.2 were included in the regression model. We examined interaction effects between variables found to be associated with HRQOL and HIV/HCV coinfection, and a stratified analysis was conducted if such effects were identified.
RESULTS

Comparison of Demographic and Clinical Characteristics
The demographic characteristics of the 299 patients enrolled in the study are shown in table 1. Patients coinfected with HIV/ HCV were more likely to be nonwhite ( ) and to have P p .024 used injection drugs ( ) and less likely to be working P ! .0001 for pay ( ) than those infected with HIV or HCV alone. P p .016 Compared with patients who were either coinfected or infected with HCV alone, patients infected with HIV alone were more likely to be homosexual ( ), to have graduated from P ! .0001 high school ( ), to have an income of more than $900/ P p .02 month ( ), and to have consumed alcohol in the pre-P p .018 vious year ( ). P ! .0001 Clinical characteristics of the 3 patient groups also differed (table 2) . HIV-infected patients had lower Karnofsky scores ( ), and HIV/HCV coinfected patients were more likely P p .03 to have had a history of depression ( ). No additional P p .04 differences in HIV parameters were noted between patients infected with HIV alone and those coinfected with HIV/HCV, nor were there differences in HCV parameters between patients infected with HCV alone and those coinfected with HIV/HCV. Two coinfected patients were receiving IFN and ribavirin therapy, and no patients infected with HCV alone were taking IFN at the time of the HRQOL evaluation.
SF-36 Results
HIV/HCV coinfected patients and those infected with HCV alone or with HIV alone had remarkably similar scores for each of the 8 subscales of the SF-36 questionnaire and the 2 summary scores (table 3) . However, the mean SF-36 scores-comprising the 8 subscales and both summary scores-of our entire combined patient group ( ) were significantly lower than n p 299 the normative scores for the US control population, adjusted for age, sex, and race ( ) ( figure 1 ). P ! .0001
Multivariate Analysis of Predictors of SF-36 Summary Scores
To identify independent predictors of HRQOL for HIV-infected and HCV-infected patients, linear regression analysis was performed using the PCS and MCS as outcome variables. 
depression ( ). HIV coinfection was associated with P p .0003 higher MCS in the HCV-infected group (
). P p .002 DISCUSSION HRQOL has been studied in patients with either HCV or HIV disease, but we believe our study is the first to examine the effect of HIV/HCV coinfection on HRQOL and to compare the HRQOL of coinfected patients with that of patients infected with either HIV or HCV alone. The patients in our study were representative of the urban HIV-and HCV-infected populations in the United States, with a predominance of minority patients and a high prevalence of injection drug use and unemployment.
Our initial hypothesis for this study was that HIV-infected patients would have a lower HRQOL, as assessed by the SF-36 questionnaire, than those infected with HCV alone. On the contrary, HRQOL was statistically similar for patients infected with HCV alone, with HIV alone, or with HIV/HCV coinfection. However, in patients with HIV and/or HCV infection, HRQOL was significantly reduced, compared with the demographically adjusted US population norms. Although the precise explanation for these data is unclear, there are several possible interpretations. First, HRQOL is a subjective evaluation of an individual's perception of their health and well-being. Carr et al. [20] have proposed that HRQOL reflects the gap between one's expectations of health and one's experience of it. Thus, our data may reflect different expectations of health in the 3 groups of patients, specifically in those infected with HIV alone, who, although having more-severe physical disease (as suggested by the significantly lower Karnofsky scores), may also have a reduced expectation of health. This is supported by the finding that, among HCV-infected patients, HIV coinfection was a predictor of higher MCS. Alternatively, patients with HIV infection may have access to additional support services that partly compensate for decrements in physical health. Another possible explanation for the similar HRQOL in these patient groups is that, in this urban population, socioeconomic factors, such as unemployment, injection drug use, and depression, have a greater impact on HRQOL than does physical illness.
The decrements in HRQOL in our 3 study groups were both statistically and clinically significant, compared with HRQOL in a sample of the US population adjusted for age, sex, and race. A meta-analysis by Samsa et al. [21] suggested that a 3-5-point difference in SF-36 scores represents a minimum clinically important difference, and Ware et al. [18] further suggested that a difference of 10 points represents a moderate effect on HRQOL. The HRQOL scores for each of the 8 subscales of the SF-36 questionnaire in our population were 110 points lower than scores for the US population sample, suggesting that HRQOL is significantly decreased in urban patients infected with HIV alone, HCV alone, or both HIV and HCV. We also analyzed PCS and MCS for the HIV-infected patients using multivariate techniques. HRQOL was not affected by HCV coinfection, CD4 cell count, or HIV load, although nonuse of HAART was associated with lower PCS. However, a stratified multivariate analysis of the interaction effects between coinfection and the variables associated with HRQOL suggested that, for HIV-infected patients, coinfection with HCV had a negative impact on MCS for patients with high Karnofsky scores and for those with a history of depression ( ). P p .02 This illustrates the complexity of looking at HRQOL in the patient population, in which multiple related variables are associated with well-being.
HIV-specific parameters, such as low CD4 cell count and high virus load, have previously been shown to adversely affect HRQOL in some studies of HIV-infected patients [15, 16] . In a study of 2864 HIV-infected adults participating in the HIV Cost and Services Utilization Study, HIV-related symptoms were the strongest predictor of HRQOL, with only weak associations with disease stage and CD4 cell count [12] . Similarly, the effect of HAART on HRQOL has been assessed, with one study showing a small improvement in HRQOL 3 months after the initiation of HAART and another suggesting that effective treatment regimens were associated with improved HRQOL over a 2-year period, compared with baseline assessments [22, 23] . We also found that HAART was associated with improved HRQOL.
In our HIV-infected cohort, demographic and social factors predominated as predictors of diminished HRQOL. These included age, foreign birth, unemployment, depression, and ongoing injection drug use. Sherbourne et al. [14] have also shown that concurrent psychiatric conditions and injection drug use were important predictors of HRQOL for patients with HIVinfection, although in this study, the effect of injection drug use was accounted for by the presence of a concurrent mood disorder.
In our study, the perceived HRQOL of patients with HCVinfection was significantly less than that of the control popu- lation. Of note, HIV coinfection did not affect PCS in the HCVinfected group, and HIV infection was actually associated with higher MCS among HCV-infected patients. However, further analysis suggested that there were significant interactions between some of the variables and that, in HCV-infected patients, HIV coinfection may have a negative impact on PCS and MCS for patients with less than a high school education (P p .06 and , respectively). In addition, HIV coinfection may P p .02 have a negative impact on MCS for HCV-infected patients with concomitant depression. Again, this illustrates the complexity of and interrelationships between the determinants of HRQOL. A recent study by Hussein et al. [24] examined unselected HCVinfected patients attending a hepatology clinic and concluded that there was no correlation between SF-36 questionnaire scores and alcohol dependence or injection drug use [24] . In the study by Hussein et al. [24] , the presence of a concurrent psychiatric illness or 11 comorbid illness was the most important predictor of HRQOL. Our study also suggested the importance of current or previous depression as independent predictors of diminished MCS in patients with HCV infection. In addition, ongoing injection drug use and unemployment were both predictive of lower HRQOL.
There are several limitations to our study. First, questionnaires were administered by trained interviewers rather than self administered. However, it has been shown that telephonebased administration of the SF-36 questionnaire yields results comparable with those of self administration [25] . Second, we relied on chart review to determine the diagnosis of past and ongoing depression and, therefore, may have misclassified patients. However, a subset of 100 patients were screened for depression using the Center for Epidemiological Studies Depression Scale, and there was a high correlation between observed scores and a diagnosis of depression (data not shown). Finally, our cross-sectional analysis of data does not address issues involving a causal relationship between the associated variables and HRQOL.
Our study also has some notable strengths. Unlike many of the published studies of HRQOL among patients with HCV infection, this study did not have the severe selection bias associated with recruitment of only those patients entering IFN treatment trials, which has the result of excluding those patients actively using injection drugs and those with mood disorders. The patients with HIV/HCV coinfection in our study are representative of the urban clinics from which they were recruitedthey are predominantly members of ethnic minority groups, three-fourths are male, and they tend to have a low income. Although 75% of coinfected participants were receiving treatment for HIV infection and ∼50% had an undetectable HIV load, nearly one-third of the participants had used injection drugs in the previous 6 months, and a similar proportion were receiving treatment for depression.
In summary, in an urban clinical setting, patients with HIV infection, HCV infection, or HIV/HCV coinfection have similar perceptions of their HRQOL, and such perceptions are significantly lower than those of the general population. Psychiatric illness, active injection drug use, and unemployment were independent predictors of diminished HRQOL scores in all patients, and non-use of HAART was associated with lower scores in patients with HIV infection. Our data underscore the impact of complex medical and psychosocial issues on HRQOL and indicate the need for specific interventions to improve HRQOL in urban clinical settings, where there is a high prevalence of substance abuse, depression, and poverty.
